SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Claris Lifesciences spurts on receiving USFDA approval for Tobramycin injection

08 Jul 2016 Evaluate

Claris Lifesciences is currently trading at Rs 230.05, up by 0.70 points or 0.31% from its previous closing of Rs 229.35 on the BSE.

The scrip opened at Rs. 230.90 and has touched a high and low of Rs. 242.00 and Rs. 224.00 respectively. So far 94338 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 266.00 on 30-Jul-2015 and a 52 week low of Rs. 126.10 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 246.05 and Rs. 212.50 respectively. The current market cap of the company is Rs. 1264.88 crore.

The promoters holding in the company stood at 60.99%, while Institutions and Non-Institutions held 21.37% and 17.64% respectively.

Claris Lifesciences has received the United States Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Tobramycin Injection USP, 80mg/2mL and 1,200mg/30mL multiple dose vials.

Tobramycin Injection is an anti-infective used to treat certain serious infections that are caused by bacteria such as meningitis and other infections of the blood, abdomen (stomach area), lungs, skin, bones, joints, and urinary tract. The estimated market size in the US is $6 million, as the product is currently in shortage list of the US drug regulator.

With this approval, Claris now has 14 approvals and 24 under approval ANDAs. The company expects more product approvals during the year, which will allow it to continue its growth in the US market.

 

Peers
Company Name CMP
Redington 234.90
Adani Enterprises 2218.35
Amrapali Industries 17.53
Rashi Peripheral 455.25
PDS 301.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×